Definium Therapeutics announces positive topline results from its Phase 3 “Voyage” study of DT120 as an oral disintegrating tablet (ODT) for generalized anxiety disorder (GAD). The company says the trial meets its primary and all key secondary efficacy endpoints. It reports that participants receiving DT120 ODT show a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) scores at Week 12 versus placebo, with a placebo-adjusted change of 5.4 points from baseline (p<0.0001) and an effect size (Cohen’s d) of 0.81.
Definium also states that DT120 ODT is generally well tolerated, citing a safety profile consistent with prior clinical experience, though details beyond that are not provided in the supplied materials. Seeking Alpha’s entry is presented as a company discussion and slideshow on the Phase 3 topline results, but the provided excerpt does not add specific new figures or endpoints beyond what is described in the Financial Post article. With only these sources provided, the main emphasis centers on efficacy outcomes at Week 12 and overall tolerability, rather than longer-term follow-up or regulatory timelines.
